Clinical Trial Update: A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia. [Phase 3]

View source ↗

Summary

This update concerns a Phase 3 study of paliperidone palmitate for preventing recurrence of schizophrenia symptoms. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Paliperidone palmitate (Paliperidone palmitate)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED